Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement.
Trapani D, Jin Q, Block CC, Freedman RA, Lin NU, Tarantino P, Mittendorf EA, King TA, Lester SC, Brock JE, Tayob N, Bunnell CA, Tolaney SM, Burstein HJ. Trapani D, et al. Among authors: burstein hj. JCO Oncol Pract. 2023 Aug;19(8):560-570. doi: 10.1200/OP.22.00731. Epub 2023 May 16. JCO Oncol Pract. 2023. PMID: 37192427
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Burstein HJ, et al. J Clin Oncol. 2003 Jan 1;21(1):46-53. doi: 10.1200/JCO.2003.03.124. J Clin Oncol. 2003. PMID: 12506169 Clinical Trial.
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Burstein HJ, et al. J Clin Oncol. 2003 Aug 1;21(15):2889-95. doi: 10.1200/JCO.2003.02.018. J Clin Oncol. 2003. PMID: 12885806 Clinical Trial.
Ductal carcinoma in situ of the breast.
Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Burstein HJ, et al. N Engl J Med. 2004 Apr 1;350(14):1430-41. doi: 10.1056/NEJMra031301. N Engl J Med. 2004. PMID: 15070793 Review. No abstract available.
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Burstein HJ, et al. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):496-504. doi: 10.1016/j.ijrobp.2005.07.975. Epub 2005 Oct 21. Int J Radiat Oncol Biol Phys. 2006. PMID: 16243442 Clinical Trial.
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Burstein HJ, et al. J Clin Oncol. 2005 Nov 20;23(33):8340-7. doi: 10.1200/JCO.2005.02.8621. J Clin Oncol. 2005. PMID: 16293865 Clinical Trial.
304 results